Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
Pozycja w akcjach #33378
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Cena akcji
$0.05124204
Kapitalizacja rynkowa
$7.78M
Zmiana (1 dzień)
0.51%
Zmiana (1 rok)
-23.73%
Kraj
CH
Handel Addex Therapeutics Ltd (ADXN)

Kategoria

Historia stopy dywidendy dla Addex Therapeutics Ltd (ADXN)
Stopa dywidendy (TTM) dla Addex Therapeutics Ltd (symbol akcji: ADXN) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Addex Therapeutics Ltd (ADXN) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji